Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41416-022-02051-7
PubMed Identifier: 36434156
Publication URI: http://europepmc.org/abstract/MED/36434156
Type: Journal Article/Review
Parent Publication: British Journal of Cancer
Issue: 3
ISSN: 0007-0920